1.18 IMpassion130 and Hot-Spotting with Dr. Brian Chan

OncologyMedicineHealth Policy
Written By Kerrington .

In this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running that tests whether Dr. Gawande's idea of "hot-spotting" -- tailoring interventions to medically complex patients -- does decrease hospitalizations. IMpassion130: doi.org/10.1056/NEJMoa1809615 Hot-spotting: https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters

Kerrington .
Previous

1.20 Precision Oncology: Some Benefit, Mostly Hype and Mentorship with Dr. Andrae Vandross
Next

1.16 BONUS! Crowdsourcing Data Analysis and Medical Reversal: Why 40% of What We Do is Wrong